Collaborative AI Study By SOPHiA GENETICS And UroCCR Offers New Hope In Kidney Cancer Treatment

In a significant stride towards enhancing kidney cancer treatment, SOPHiA GENETICS and the French Kidney Cancer Research Network (UroCCR) have unveiled findings from their latest study. Published in npj Precision Oncology, the research showcases an artificial intelligence (AI) model adept at predicting post-operative outcomes for renal cell carcinoma (RCC) patients. This AI model, a product of the collaboration between the cloud-native software company and UroCCR, stands out for its accuracy in forecasting patient prognoses post-surgery, surpassing traditional prognostic scores.

The partnership between SOPHiA GENETICS and UroCCR is not new; it builds on previous research that underscored the value of multimodal analysis in pre-operative kidney cancer staging. UroCCR, a prominent network comprising 51 multidisciplinary clinical teams across France, aims to foster connections among medical and scientific professionals to advance therapeutic management and applied research in kidney cancer.

In 2021, this collaboration bore fruit with the development of an AI-based model designed to predict the progression of kidney cancer post-surgery. Utilizing data from over 3,300 patients, including radiological, clinical, and biological information, the model demonstrated superior performance over most common risk scores.

Thierry Colin, VP of Multimodal Research and Development at SOPHiA GENETICS, highlighted the synergy between AI and the growing complexity of health data. He praised the advancements in RCC research facilitated by their partnership with UroCCR and looked forward to future collaborative efforts.

The study underscores the potential of AI-based prediction models in supporting clinical decision-making and identifying patients who might benefit from adjuvant systemic therapy. It also sheds light on precision medicine's role in kidney cancer treatment.

Pr Jean-Christophe Bernhard, a Urologic Surgeon at CHU Bordeaux and head of UroCCR, lauded the application of AI in analyzing real-world multimodal data. He attributed the success of their research to SOPHiA GENETICS' technology and network, emphasizing the importance of increasing data inputs for future advancements.

Established in 2011 and supported by the French National Cancer Institute, UroCCR serves as a comprehensive database for clinical, biological, and radiological data on newly diagnosed kidney cancer patients. It has gained recognition as a valuable real-life data provider by the High Authority on Health.

SOPHiA GENETICS' SOPHiA DDM™ Platform leverages cloud-based AI to analyze multimodal data for developing predictive models. This platform is globally utilized by hospitals, laboratories, and biopharma institutions.

This collaboration between SOPHiA GENETICS and UroCCR not only highlights AI's potential in cancer research but also its capability to provide actionable insights for precision medicine through the analysis of real-world multimodal data.